Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine
复制标题
DOI：
10.1016/j.vaccine.2009.07.027
复制
发表时间：
2009-09-18
期刊：
影响因子：
5.5
通讯作者：
Koutsky, Laura A.
中科院分区：
文献类型：
--
作者：
Rowhani-Rahbar, Ali;Mao, Constance;Koutsky, Laura A.
我们进行了一项延长的随访研究(2006年3月至2008年5月)，以评估预防性单价人乳头瘤病毒(HPV)16型L1病毒样颗粒疫苗在西雅图参加该疫苗的随机对照试验(1998年10月至1999年11月)且在试验过程中HPV-16DNA阴性的女性(n=290)的长期疗效。在延长的随访期内，在按方案接种的易感人群中，没有一名疫苗接受者被发现感染HPV-16或发生HPV-16相关宫颈病变：在安慰剂接受者中，6名妇女被发现感染HPV-16(疫苗疗效[VE]=100%；95%可信区间[CI]：29-100%)，3名妇女发生HPV-16相关宫颈病变(VE=100%；95%CI：
We conducted an extended follow-up study (March 2006-May 2008) to assess the longer term efficacy of a prophylactic monovalent human papillomavirus (HPV) type 16 L1 virus-like particle vaccine in women (n = 290) who had enrolled in a randomized controlled trial of this vaccine (October 1998-November 1999) in Seattle and remained HPV-16 DNA negative during the course of that trial. During the extended follow-up period, in the per-protocol susceptible population, none of the vaccine recipients was found to be infected with HPV-16 or developed HPV-16-related cervical lesions: among placebo recipients, 6 women were found to be infected with HPV-16 (vaccine efficacy [VE] = 100%; 95% confidence interval [CI]: 29-100%) and 3 women developed HPV-16-related cervical lesions (VE = 100%; 95% CI: